Levels of transforming growth factor β1 during first six months of peritoneal dialysis

References

• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease role of transforming growth factor β in human disease. N Engl J Med. 2000;342:1350–1358
   PubMed Web of Science ®Google Scholar
• Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGFβ – A good servant but a bad master. J Transl Med. 2012;10:183. doi: 10.1186/1479-5876-10-183
   PubMed Web of Science ®Google Scholar
• Lawrence DA. Transforming growth factor-β: A general review. Eur Cytokine New. 1996;7:363–374
   PubMed Web of Science ®Google Scholar
• Janda K, Krzanowski M, Dumnick P, Kusnierz-Cabala A, Sulowicz W. Transforming growth factor beta 1 as a risk factor for cardiovascular disease in end-stage renal disease patients treated with peritoneal dialysis. Clin Lab. 2014;60(7):1163–1168
   PubMedGoogle Scholar
• Ueno T, Nakashima A, Doi S, et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int. 2013;84(2):297–307
   PubMedGoogle Scholar
• McLoughlin RM, Topley N. Switching on EMT in the peritoneal membrane: Considering the evidence. Nephrol Dial Transplant. 2011;26:12–15
   PubMedGoogle Scholar
• Hung KY, Wu KD, Tsai TJ. In vitro study of peritoneal fibrosis. Perit Dial Int. 2007;27(Supl. 2):S72–S75
   Google Scholar
• Honda K, Kamada C, Nayama M, et al. Impact of uremia, diabetes and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: A quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3:720–728
   PubMedGoogle Scholar
• Margetts P, Bonniaud P, Liu L, et al. Transient overexpression of TgF-β1 induces epithelial mesenchymal transition in rodent peritoneum. J Am Soc Nephrol. 2005;16:425–436
   PubMed Web of Science ®Google Scholar
• Garosi G. Different aspects of peritoneal damage: Fibrosis and sclerosis. In: Crepaldi C, Cruz DN, eds. Peritoneal Dialysis – From Basic Concepts to Clinical Excellence. Contributions to Nephrology. Vol. 163. Basel: Karger; 2009:45–53
   Google Scholar
• Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factored extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002;22:171–177
   PubMed Web of Science ®Google Scholar
• Randall JF. Bad and good growth factors in the peritoneal cavity. Nephrology. 2005:10:234–239
   PubMedGoogle Scholar
• Al-Jayyousi RH, Medcalf JF, Harris KPG. Role of transforming growth factor beta in peritoneal fibrosis. Nephrology. 2002;7:216–219
   Google Scholar
• Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor beta to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol. 2001;12:2029–2039
   PubMed Web of Science ®Google Scholar
• Lin CY, Chen WP, FU LW, Huan TP. Persistent transforming growth factor β expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Adv Perit Dial. 1997;13:64–71
   PubMedGoogle Scholar
• Stompor T, Zdzienicka A, Motyka M, Dembinska-Kiec A, Davies SJ, Sulowicy W. Selected growth factors in peritoneal dialysis: Their relationship to markers of inflammation, dialysis adequacy, residual renal function and peritoneal membrane transport. Perit Dial Int. 2002;22:670–676
   PubMed Web of Science ®Google Scholar
• Zweers MM, deWaart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF in peritoneal dialysis. J Lab Clin Med. 1999;134:124–132
   PubMed Web of Science ®Google Scholar
• Devuyst O. Molecular mechanisms of peritoneal permeability – Research in growth factors. Perit Dial Int. 2001;21:S19–S23
   Google Scholar
• Jones S, Clifford JH, Krediet RT, et al., on behalf of the Bicarbonate/Lactate Study Group. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int. 2001;59:1529–1538
   PubMedGoogle Scholar
• Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: A prospective randomized study. Nephrol Dial Transplant. 2004;19:2101–2106
   PubMedGoogle Scholar
• Theodoridis M, Thodis B, Tsigalou C, et al. Alterations of dialysate markers in chronic peritoneal dialysis patients treated with the new less biocompatible solutions. Perit Dial Int. 2011;31:196–199
   PubMedGoogle Scholar
• Weiss L, Stegmayr B, Malmsten G, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int. 2009;29:647–655
   PubMedGoogle Scholar
• Jing S, Kezhou Y, Hong Z, Qun W, Rong W. Effects of renin–angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton). 2010;15(1):27–32
   PubMedGoogle Scholar
• Lee CJ, Subeq YM, Lee RP, Liou HH, Hsu BG. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats. Cytokine. 2014;65(1):105–118
   PubMedGoogle Scholar
• Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oroepoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial. 2004;20:31–36
   PubMedGoogle Scholar
• Dinarvand P, Farhadian S, Seyedjafari E, et al. Novel approach to reduce postsurgical adhesions to a minimum: Administration of losartan plus atorvastatin intraperitoneally. J Surg Res. 2013;181(1):91–98
   PubMed Web of Science ®Google Scholar
• Mondello S, Mazzon E, Di Paola R, et al. Erythropoietin suppresses peritoneal fibrosis in rat experimental model. Eur J Pharmacol. 2009;604:138–149
   PubMedGoogle Scholar